Summary The U.S. and U.K. have reached a trade deal that will exempt drugs imported from the U.K. from tariffs for three years in exchange for pricing concessions. This agreement
Conclusions & Strategic Implications What great looks like; near-term moves for R&D and access teams; mid-term capabilities roadmap. Appendices Glossary (HTA, QALY, ICER, BIA, IRP, MEA, VPAG, etc.) Abbreviated methodological
Operating Model, Governance & Ways of Working End-to-end market access strategy frame: What is the winning ambition? Where to play? How to win? How to execute? (decision gates, RASIC, KPIs).
Economic evaluation 101 Economic evaluation compares alternative health interventions by examining both their costs and their consequences, enabling decision-makers to allocate resources efficiently. In health care, this is a structured,
Understanding how different markets and product types shape pricing, reimbursement, and access strategies. Global Market Access Models (Short “How It Works” Overviews) United States Europe / HTA-driven systems (conceptual) Japan
What Is Market Access in Pharma, Why It Matters, and How Disciplines and Stakeholders Intersect Executive Summary Market access is the set of activities that ensure a medicine is
Market Access Across the Development Pathway includes Discovery / Pre-clinical: early unmet need mapping; target product profile (TPP) with payer-relevant claims; landscape scan (customers, competition, context). Phase 1–2: endpoint selection
Learn how MARA Rating’s Uncertainty & Sensitivity domain (A++–C) predicts HTA outcomes; why 2.6 vs 2.0 scores sway payer trust, pricing & reimbursement. Since 2020, we’ve seen a clear split:
Many breakthrough therapies in the U.S. stumble in their first year on the market, despite strong clinical promise. The reason isn’t usually safety or efficacy. It’s cost pressures, evidence maturity, and system
About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against